Clinical Researcher—June 2026 (Volume 40, Issue 3)
CHAIR’S MESSAGE
Mo Ali, 2026 Chair of the Association Board of Trustees for ACRP
Clinical development organizations are no longer asking whether artificial intelligence (AI), automation, and modern data architectures belong in research and development (R&D). The question in 2026 is far more urgent: “Which organizations can operationalize them fast enough to materially improve speed, quality, cost, and decision-making before competitive pressure forces transformation upon them?”
Quite a few pharmaceutical organizations are already shifting away from fragmented study execution toward connected intelligence ecosystems. Clinical operations, safety, regulatory, translational science, biometrics, and portfolio strategy are beginning to converge around shared data products, semantic business layers, and AI-enabled workflows designed to reduce friction across the development lifecycle.
The implications are significant. At the center of this transformation is a realization many organizations resisted for years: AI does not solve fragmented operating models. It amplifies them.
Organizations that continue to treat data as isolated system outputs will struggle to scale AI meaningfully. Successful transformation now depends on creating governed, reusable, domain-owned data products with clear stewardship, standardized definitions, traceability, and embedded quality controls. For example, clinical operations data cannot exist independently from safety signals, biomarker insights, protocol amendments, or portfolio prioritization decisions—especially if the ask is for insights and not just metrics. The future state needs to be interconnected by design.
This is where the concepts of semantic architectures and knowledge graphs become operationally critical rather than theoretical. A semantic layer provides consistent business meaning across systems, metrics, and workflows. A knowledge graph creates contextual relationships between studies, investigators, patients, endpoints, compounds, deviations, risks, vendors, and outcomes. Together, they enable AI systems to reason across connected evidence rather than isolated datasets.
Taking the Next Steps
There are a few practical next steps I would recommend for industry leaders moving in this direction to help enable this new way of working.
First, organizations must move beyond enterprise reporting programs and establish formal data product operating models across their portfolio R&D domains. Ownership, governance, quality accountability, and reusable standards must sit within the business as a whole, not exclusively within the information technology team.
Second, AI initiatives should prioritize embedded workflow augmentation over standalone experimentation. The highest return will come from connected AI copilots integrated directly into your data product catalog, showing associated data lineage. Examples include protocol review, study oversight, risk management, medical writing, and portfolio governance processes.
Third, sponsors and contract research organizations must modernize data ingestion and oversight models. Continuous ingestion pipelines, automated anomaly detection, metadata-driven lineage, and near real-time operational monitoring will increasingly replace static reconciliation cycles and delayed reporting.
Fourth, organizations must invest in trust. Transparent governance, explainable AI outputs, human review controls, and measurable validation frameworks will determine whether AI becomes enterprise infrastructure or remains trapped in pilot mode.
Think About It
The next era of clinical research will not be defined by isolated technologies. It will be defined by how effectively organizations connect people, data, workflows, and intelligence into a scalable development ecosystem capable of accelerating evidence generation without compromising scientific rigor or patient trust.
The future of clinical research is not digital alone. It is connected, governed, predictive, and profoundly human.
⊕⊕ACRP⊕⊕
